title: The Long Road to an Effective Vaccine for Meningococcus Group B (MenB).
abstract: Neisseria meningitidis infection can cause life-threatening meningitis and meningococcal septicaemia. Over the past 40 years, vaccines against most of the main meningococcal serogroups have offered increasingly good protection from disease, with one major exception in the developed world: serogroup B meningococcus (MenB). In the United States, MenB accounts for about a quarter of cases of meningococcal meningitis, with the bulk of the rest caused by meningococcus serogroups C (MenC) and Y (MenY). In the UK, where a vaccine against MenC is widely used, MenB is now responsible for nearly 90% of cases of invasive meningococcal disease. Recent attempts to create a universal MenB vaccine have been thwarted by the variability of the surface proteins of MenB and by the similarity of the MenB capsule to human glycoproteins. This review discusses current meningococcal vaccine strategies and their limitations with regard to MenB, and examines a promising new strategy for the rational design of a MenB vaccine. Thanks to a fusion of a rational reverse genetics approach and a membrane vesicle approach, a MenB vaccine, 4CMenB (Bexsero(®)), has finally gained regulatory approval in Europe and could be in clinical use by the end of 2013.
authors: St. Hugh's College, University of Oxford, Oxford, OX2 6LE, UK.
authors: Michael W
authors: MW
authors: Shea
keywords: Evidence Based Medicine; Mass Media; Misrepresentation; Randomised Controlled Trials
references: PLoS One. 2012;7(1):e29116
references: 22276104
references: Vaccine. 2010 Jul 12;28(31):5057-67
references: 20653107
references: Lancet. 2013 Mar 9;381(9869):825-35
references: 23324563
references: Clin Vaccine Immunol. 2010 May;17 (5):840-7
references: 20219881
references: Infect Immun. 1991 Feb;59(2):732-6
references: 1898915
references: J Infect Dis. 1972 Nov;126(5):514-21
references: 4197754
references: J Infect Dis. 2007 May 15;195(10):1472-9
references: 17436227
references: Infect Immun. 2007 Nov;75(11):5434-42
references: 17664268
references: Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3770-5
references: 20133713
references: J Exp Med. 1969 Jun 1;129(6):1307-26
references: 4977280
references: FEMS Microbiol Rev. 2011 May;35(3):498-514
references: 21204865
references: Lancet. 2012 Feb 4;379(9814):461-73
references: 21903253
references: Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):10834-9
references: 16825336
references: Arch Pediatr Adolesc Med. 2005 Oct;159(10):907-13
references: 16203934
references: JAMA. 2012 Feb 8;307(6):573-82
references: 22318278
references: Clin Infect Dis. 2011 Nov;53(9):e117-24
references: 21946191
references: J Immunol. 2006 Jul 1;177(1):501-10
references: 16785547
references: Clin Infect Dis. 2010 Nov 15;51(10 ):1127-37
references: 20954968
references: J Med Microbiol. 2008 Mar;57(Pt 3):338-42
references: 18287297
references: Vaccine. 2009 Jun 24;27 Suppl 2:B3-12
references: 19481313
references: Hum Vaccin. 2011 Jul;7(7):781-91
references: 21734467
references: Discov Med. 2011 Jul;12(62):7-15
references: 21794204
references: J Infect Dis. 2011 Oct 1;204(7):1046-53
references: 21881120
references: Clin Infect Dis. 2011 Feb;52 Suppl 3:s253-8
references: 21217172
references: Lancet. 2012 Feb 18;379(9816):617-24
references: 22260988
references: Lancet. 1991 Nov 2;338(8775):1093-6
references: 1682541
references: Nat Rev Immunol. 2006 Feb;6(2):148-58
references: 16491139
references: Infect Immun. 1982 Dec;38(3):1203-7
references: 6818147
references: Vaccine. 2012 May 30;30 Suppl 2:B67-72
references: 22230578
references: J Infect Dis. 2009 May 1;199(9):1360-8
references: 19302008
references: J Immunol. 1987 Jun 15;138(12):4402-7
references: 3108388
references: Vaccine. 1996 Jul;14(10):1001-8
references: 8873395
references: J Infect Dis. 2006 Dec 15;194(12 ):1745-52
references: 17109348
references: Mol Cell. 1999 Apr;3(4):435-45
references: 10230396
references: Science. 2000 Mar 10;287(5459):1816-20
references: 10710308
references: J Infect Dis. 2008 Mar 1;197(5):737-43
references: 18271745
references: Clin Vaccine Immunol. 2010 Jun;17(6):919-29
references: 20375242
references: Vaccine. 2012 May 21;30(24):3710-6
references: 22429756
references: Clin Microbiol Rev. 1989 Apr;2 Suppl:S118-24
references: 2655881
references: J Exp Med. 2002 Jun 3;195(11):1445-54
references: 12045242
references: JAMA. 1999 Apr 28;281(16):1520-7
references: 10227322
references: Infect Immun. 2009 May;77(5):2084-93
references: 19289516
references: J Exp Med. 1969 Jun 1;129(6):1327-48
references: 4977281
references: Clin Infect Dis. 1999 Jan;28(1):98-105
references: 10028078
references: Vaccine. 2013 Feb 4;31(7):1113-6
references: 23261039
references: BMJ. 2012 Nov 20;345:e7867
references: 23169828
references: Science. 2000 Mar 10;287(5459):1809-15
references: 10710307
references: Clin Exp Immunol. 1998 Dec;114(3):362-9
references: 9844044
references: Vaccine. 1999 Aug 20;18(1-2):160-72
references: 10501246
references: Vaccine. 2009 Jun 24;27 Suppl 2:B51-63
references: 19477562
references: J Infect Dis. 2003 Dec 1;188(11):1730-40
references: 14639545
references: PLoS Genet. 2011 Jan 20;7(1):e1001277
references: 21283790
references: Clin Vaccine Immunol. 2006 Apr;13(4):486-91
references: 16603616
references: Vaccine. 2005 Mar 18;23(17-18):2222-7
references: 15755600
references: PLoS Pathog. 2012;8(5):e1002688
references: 22589720
references: Expert Rev Vaccines. 2011 Jan;10(1):21-33
references: 21162617
references: Clin Vaccine Immunol. 2011 Jun;18(6):1002-14
references: 21508163
references: Vaccine. 2011 Oct 13;29(44):7752-8
references: 21827811
references: Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7175-9
references: 1908091
references: Clin Vaccine Immunol. 2010 Sep;17(9):1460-6
references: 20660140
references: Emerg Infect Dis. 2004 Apr;10(4):674-8
references: 15200858
references: J Exp Med. 2003 Mar 17;197(6):789-99
references: 12642606
references: Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):17871-5
references: 22025709